All News

2021

September

Media Release / Sep 21, 2021

Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss

Read More
Media Release / Sep 19, 2021

Novartis announces collaboration on HARMONIA, a Phase III, head-to-head trial evaluating Kisqali® vs. Ibrance®* in patients with HR+/HER2- advanced breast cancer

Read More
Media Release / Sep 19, 2021

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

Read More
Media Release / Sep 17, 2021

Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)

Read More
Media Release / Sep 17, 2021

Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021

Read More
Media Release / Sep 13, 2021

Novartis announces first FDA filing acceptance for anti-PD-1 antibody tislelizumab for people with esophageal cancer

Read More
Media Release / Sep 08, 2021

Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine

Read More
Media Release / Sep 03, 2021

Novartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions

Read More
Media Release / Sep 01, 2021

World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran)

Read More

August

Media Release / Aug 30, 2021

Novartis Leqvio®* (inclisiran) analyses show effective and sustained LDL-C reduction in two sub-populations of patients with ASCVD

Read More

Key Releases

Ad hoc announcement pursuant to article 53 Listing Rules.

Learn More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More